Bayer Healthcare Company Profile

✉ Email this page to a colleague

BAYER HEALTHCARE has twenty-nine approved drugs.

There are twenty-eight US patents protecting BAYER HEALTHCARE drugs. There is one tentative approval on BAYER HEALTHCARE drugs.

There are four hundred and twenty-nine patent family members on BAYER HEALTHCARE drugs in fifty-nine countries and fifty supplementary protection certificates in seventeen countries.

International Patents:	429
US Patents:	28
Tradenames:	24
Ingredients:	14
NDAs:	29
Patent Litigation for Bayer Healthcare:	See patent lawsuits for Bayer Healthcare

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Healthcare Llc	CLARITIN REDITABS	loratadine	TABLET, ORALLY DISINTEGRATING;ORAL	021993-001	Dec 12, 2006		OTC	Yes	Yes		⤷ Sign Up				⤷ Sign Up
Bayer Healthcare Llc	CLARITIN-D	loratadine; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	019670-002	Nov 27, 2002		OTC	Yes	Yes		⤷ Sign Up				⤷ Sign Up
Bayer Healthcare	VITRAKVI	larotrectinib sulfate	SOLUTION;ORAL	211710-001	Nov 26, 2018		RX	Yes	Yes	11,191,766	⤷ Sign Up				⤷ Sign Up
Bayer Healthcare Llc	CHLOR-TRIMETON	chlorpheniramine maleate; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	018397-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No		⤷ Sign Up				⤷ Sign Up
Bayer Healthcare	VITRAKVI	larotrectinib sulfate	SOLUTION;ORAL	211710-001	Nov 26, 2018		RX	Yes	Yes	10,774,085	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Healthcare Llc	CLARITIN REDITABS	loratadine	TABLET, ORALLY DISINTEGRATING;ORAL	020704-002	Nov 27, 2002	4,659,716*PED	⤷ Sign Up
Bayer Healthcare Llc	CLARITIN-D 24 HOUR	loratadine; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	020470-002	Nov 27, 2002	4,863,931*PED	⤷ Sign Up
Bayer Healthcare Llc	MYCELEX	clotrimazole	CREAM;TOPICAL	018183-001	Approved Prior to Jan 1, 1982	3,705,172	⤷ Sign Up
Bayer Healthcare Llc	CLARITIN	loratadine	TABLET;ORAL	019658-002	Nov 27, 2002	4,659,716*PED	⤷ Sign Up
Bayer Healthcare Llc	CLARITIN-D	loratadine; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	019670-002	Nov 27, 2002	4,863,931*PED	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2493858	CA 2020 00020	Denmark	⤷ Sign Up	PRODUCT NAME: DAROLUTAMID EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT ELLER EN FARMACEUTISK ACCEPTABELT ESTER DERAF; REG. NO/DATE: EU/1/20/1432/001 20200330
2493858	PA2020514	Lithuania	⤷ Sign Up	PRODUCT NAME: DAROLUTAMIDAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA ARBA ESTERIS; REGISTRATION NO/DATE: EU/1/20/1432 20200327
2493858	122020000030	Germany	⤷ Sign Up	PRODUCT NAME: DAROLUTAMID; NAT. REGISTRATION NO/DATE: EU/1/20/1432 20200327; FIRST REGISTRATION: EU EU/ 1/2011432 20200327
3106463	CR 2020 00013	Denmark	⤷ Sign Up	PRODUCT NAME: LAROTRECTINIB OG/ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SAERLIGT LAROTRECTINIBSULFAT, INKLUSIV LAROTRECTINIBHYDROGENSULFAT; REG. NO/DATE: EU/1/19/1385 20190923
3106463	SPC/GB20/013	United Kingdom	⤷ Sign Up	PRODUCT NAME: LAROTRECITINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PARTICULARLY LAROTRECITINIB SULFATE INCLUDING LAROTRECITINIB HYDROGEN SULFATE; REGISTERED: UK EU/1/19/1385(NI) 20190923; UK PLGB 00010/0741 20190923; UK PLGB 00010/0742 20190923; UK PLGB 00010/0743 20190923
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.